

VYVGART® Hytrulo

(efgartigimod alfa and hyaluronidase-qvfc)

Subcutaneous Injection
180 mg/mL and 2000 U/mL vial

**A NEW class
of treatment NOW
FDA-approved
for CIDP**



CIDP=chronic inflammatory demyelinating polyneuropathy

What is VYVGART® HYTRULO (efgartigimod alfa and hyaluronidase-qvfc)?

VYVGART HYTRULO is a prescription medicine used for the treatment of adult patients with chronic inflammatory demyelinating polyneuropathy (CIDP)

SELECT IMPORTANT SAFETY INFORMATION

Do not use VYVGART HYTRULO if you have a serious allergy to efgartigimod alfa, hyaluronidase, or any of the other ingredients in VYVGART HYTRULO. VYVGART HYTRULO can cause serious allergic reactions and a decrease in blood pressure leading to fainting.

Please see Important Safety Information throughout. Please see the full Prescribing Information for VYVGART HYTRULO.

A one-of-a-kind treatment for a one-of-a-kind you

Chronic inflammatory demyelinating polyneuropathy (CIDP) is a rare condition that affects a small percentage of the population and can have an impact on many aspects of life, like daily activities with family and friends.

Is it time for a different approach to treating CIDP? Talk to your doctor about VYVGART Hytrulo.

A different approach to CIDP

- ✔ The first new class of CIDP treatment in over 30 years
- ✔ Works differently than other CIDP treatments, including IVIg, SCIg, PLEX, and steroids
- ✔ The first and only plasma-free treatment approved by the FDA for CIDP
- ✔ A first for CIDP—one weekly injection, given under the skin by a healthcare professional, that takes ~30 to 90 seconds*

*After administering your injection, your healthcare provider will monitor you for allergic reactions for at least 30 minutes.
CIDP=chronic inflammatory demyelinating polyneuropathy; IVIg=intravenous immunoglobulin; PLEX=plasma exchange; SCIg=subcutaneous immunoglobulin

SELECT IMPORTANT SAFETY INFORMATION

VYVGART HYTRULO may cause serious side effects, including infection. VYVGART HYTRULO may increase the risk of infection. The most common infections for efgartigimod alfa-fcab-treated patients were urinary tract and respiratory tract infections. Signs or symptoms of an infection may include fever, chills, frequent and/or painful urination, cough, pain and blockage of nasal passages/sinus, wheezing, shortness of breath, fatigue, sore throat, excess phlegm, nasal discharge, back pain, and/or chest pain.

Please see Important Safety Information throughout. Please see the full Prescribing Information for VYVGART HYTRULO.




Hitting the links with style.

o that's living
VYVIDLY

CIDP affects every body differently

CIDP is an autoimmune disease, which means that your immune system is mistakenly attacking you instead of protecting you.

In some people with CIDP, the immune system produces **harmful immunoglobulin (IgG) antibodies** that work against you, along with the **IgG antibodies** that work to protect you.



What causes CIDP symptoms

Your nerves have a protective layer around them called **myelin**. Damage to the myelin over time makes it harder for signals to travel quickly along the nerve. That means signals to and from the arms or legs may slow down or, in some cases, be lost completely.

The role of IgG antibodies

Although the complete cause of CIDP is not fully understood, recent studies suggest that, in some people, **harmful IgG antibodies** may be involved in damaging the myelin.

The impact on daily activities

Physical symptoms like muscle weakness, tingling, or numbness can affect your ability to perform daily tasks. Damage to the myelin is why some people experience CIDP symptoms. In some cases, the damage may be debilitating and irreversible.

CIDP=chronic inflammatory demyelinating polyneuropathy; IgG=immunoglobulin G

SELECT IMPORTANT SAFETY INFORMATION

VYVGART HYTRULO may cause serious side effects, including allergic reactions (hypersensitivity reactions). VYVGART HYTRULO can cause allergic reactions such as rashes, swelling under the skin, and shortness of breath. Hives were also observed in patients treated with VYVGART HYTRULO. Serious allergic reactions, such as trouble breathing and decrease in blood pressure leading to fainting have been reported with efgartigimod alfa-fcab.

Please see Important Safety Information throughout. Please see the full Prescribing Information for VYVGART HYTRULO.

VYVGART Hytrulo is designed differently


VYVGART Hytrulo is specifically designed to cause a reduction in the number of IgG antibodies, including harmful IgG antibodies.

VYVGART Hytrulo has 2 active ingredients: efgartigimod alfa and hyaluronidase (human recombinant), which helps to increase the distribution and absorption of ingredients into the body.



The role of FcRn receptors

When antibodies, including harmful ones, attach to receptors called **FcRn**, their time in the body is extended. Those that don't attach to FcRn receptors are removed by the body.



VYVGART Hytrulo attaches to FcRn receptors

VYVGART Hytrulo is designed to attach to FcRn receptors. By keeping some FcRn receptors occupied, more IgG antibodies remain unattached.



Reduction in IgG antibodies

When IgG antibodies, including **harmful IgG antibodies**, cannot attach to an FcRn receptor, they are removed by the body.

CIDP=chronic inflammatory demyelinating polyneuropathy; FcRn=neonatal Fc receptor; IgG=immunoglobulin G

SELECT IMPORTANT SAFETY INFORMATION

VYVGART HYTRULO may cause serious side effects, including infusion-related reactions. VYVGART HYTRULO can cause infusion-related reactions. The most frequent symptoms and signs reported with efgartigimod alfa-fcab were high blood pressure, chills, shivering, and chest, abdominal, and back pain.

Please see Important Safety Information throughout. Please see the full Prescribing Information for VYVGART HYTRULO.

The effectiveness of VYVGART Hytrulo was established in 2 stages of a clinical study

Stage A

- **Goal:** Identify patients who showed **symptom improvements with VYVGART Hytrulo** at 2 consecutive visits. These patients **moved onto stage B**
- **Symptom improvements were measured using 1 of the following:**
 - Arm and leg function (aINCAT)
 - Grip strength
 - Ability to perform 24 daily activities, such as walking, showering, and dressing (I-RODS)
- All 322 patients in stage A received VYVGART Hytrulo

Improved symptoms



~7 out of 10 patients (221 out of 322) on VYVGART Hytrulo experienced improvements and moved onto stage B.

The study included patients who had:

✓ Different types of CIDP (typical, distal, multifocal, and motor)

✓ Never been treated for CIDP

✓ Been previously treated for CIDP with IVIg, SCIg, or steroids

aINCAT=adjusted Inflammatory Neuropathy Cause and Treatment; CIDP=chronic inflammatory demyelinating polyneuropathy; I-RODS=Inflammatory Rasch-built Overall Disability Scale; IVIg=intravenous immunoglobulin; SCIg=subcutaneous immunoglobulin

SELECT IMPORTANT SAFETY INFORMATION

Tell your doctor if you have signs or symptoms of an infection, allergic reaction, or infusion-related reaction. These can happen while you are receiving your VYVGART HYTRULO treatment or afterward. Your doctor may need to pause or stop your treatment. Contact your doctor immediately if you have signs or symptoms of a serious allergic reaction.

Please see Important Safety Information throughout. Please see the full Prescribing Information for VYVGART HYTRULO.

VYVGART Hytrulo significantly reduced the risk of CIDP getting worse

Stage B (main part of the study)

- **Main study goal:** From the start of stage B, determine how long **arm and leg function was maintained without getting worse** for patients who continued on VYVGART Hytrulo, compared to those who were moved onto placebo
- Arm and leg function (aINCAT) was measured weekly
- 111 patients continued on VYVGART Hytrulo, and 110 patients were moved onto placebo

Maintained function

Patients who continued on VYVGART Hytrulo **maintained their level of arm and leg function longer** than patients who were moved onto placebo.

Reduced risk of CIDP getting worse

The risk of CIDP getting worse **was 61% lower** for patients taking VYVGART Hytrulo, compared to those who were moved onto placebo.



99% of eligible patients chose to be part of an extended safety study and receive VYVGART Hytrulo (226 out of 228 patients)

aINCAT=adjusted Inflammatory Neuropathy Cause and Treatment; CIDP=chronic inflammatory demyelinating polyneuropathy

SELECT IMPORTANT SAFETY INFORMATION

Before taking VYVGART HYTRULO, tell your doctor if you: take any medicines, including prescription and non-prescription medicines, supplements, or herbal medicines; have received or are scheduled to receive a vaccine (immunization); or have any allergies or medical conditions, including if you are pregnant or planning to become pregnant, or are breastfeeding.

Please see Important Safety Information throughout. Please see the full Prescribing Information for VYVGART HYTRULO.

An established safety profile


When considering treatment, talking to your doctor about the potential benefits and side effects can help you know what to expect.

Most common side effects

- Respiratory tract infection
- Headache
- Urinary tract infection
- Tingling sensation
- Muscle pain
- Injection site reaction

Most common injection site reactions

- Injection site rash
- Redness of the skin
- Itching sensation
- Bruising
- Pain
- Hives

 All injection site reactions were mild to moderate

 Most injection site reactions occurred during the first 3 months of treatment

VYVGART Hytrulo may increase the risk of allergic reactions including rash, swelling under the skin, shortness of breath, and hives. It may also increase the risk of serious allergic reactions such as trouble breathing and decrease in blood pressure leading to fainting, as well as infusion-related reactions including increase in blood pressure, chills, shivering, and chest, abdominal, and back pain. These reactions can occur during or after treatment and can cause doctors to pause or, in some cases, stop treatment.

These are not all the possible side effects of VYVGART Hytrulo. Call your doctor for medical advice about side effects. You may report side effects to the US Food and Drug Administration at 1-800-FDA-1088.

Please see Important Safety Information throughout. Please see the full Prescribing Information for VYVGART HYTRULO.



The safety of VYVGART Hytrulo was evaluated in the largest clinical study in CIDP history



Considering VYVGART Hytrulo?

Ask your doctor if VYVGART Hytrulo is right for you. If you are considering VYVGART Hytrulo and looking for more resources, the VYVGART Hytrulo Education Line can help you find the answers. Our experts are available 6 days a week (Monday through Saturday, 8 AM to 9 PM ET).

Call 1-833-VYV-CIDP (1-833-898-2437) to speak with an educator.

The first subcutaneous injection approved for CIDP



One injection given weekly that takes **~30 to 90 seconds.***



A single subcutaneous injection, delivered under the skin, that **does not require vein access.**



Given at a **doctor's office, infusion center, or at home** by a healthcare professional.†

*After administering your injection, your healthcare provider will monitor you for allergic reactions for at least 30 minutes.

†In some cases, VYVGART Hytrulo may also be given at home by a trained nurse.

CIDP=chronic inflammatory demyelinating polyneuropathy

SELECT IMPORTANT SAFETY INFORMATION

The most common side effects in efgartigimod-alfa-fcab-treated patients were respiratory tract infection, headache, and urinary tract infection. Additional common side effects with VYVGART HYTRULO are injection site reactions, including rash, redness of the skin, itching sensation, bruising, pain, and hives. These are not all the possible side effects of VYVGART HYTRULO. Call your doctor for medical advice about side effects. You may report side effects to the US Food and Drug Administration at 1-800-FDA-1088.

Please see Important Safety Information throughout. Please see the full Prescribing Information for VYVGART HYTRULO.



*Up for a game...
and down for a little competition.*

o that's living
VIVIDLY




Personalized support throughout your journey


A Nurse Case Manager is here for you

It may feel overwhelming getting started on a new treatment. With My VYVGART Path, you'll have access to resources and one-on-one support.

My VYVGART Path is a Patient Support Program that pairs you with a dedicated Nurse Case Manager (NCM), who can help you navigate insurance, offer resources, talk through your challenges, and more.



What you can expect from your NCM




A personalized understanding of your treatment

My VYVGART Path NCMs are knowledgeable about VYVGART Hytrulo and are dedicated to listening to you and answering any questions you may have.



Empowering resources and information

NCMs can support you throughout your treatment journey to help you in following your doctor's treatment plan.



Hands-on help navigating the insurance process

Dealing with insurance can be complicated. An NCM can help answer any questions you have, help you understand the process, and verify what is covered by your insurance.



Helpful information about a co-pay program and financial assistance programs

If you have financial concerns or gaps in insurance coverage for your VYVGART Hytrulo therapy, an NCM is here for you with information and support.

Already taking VYVGART Hytrulo?
A Nurse Case Manager is ready to help you.

**Give them a call at:
1-833-MY-PATH-1 (1-833-697-2841)**

IMPORTANT SAFETY INFORMATION

What is VYVGART® HYTRULO (efgartigimod alfa and hyaluronidase-qvfc)?

VYVGART HYTRULO is a prescription medicine used for the treatment of adult patients with chronic inflammatory demyelinating polyneuropathy (CIDP)

IMPORTANT SAFETY INFORMATION

Do not use VYVGART HYTRULO if you have a serious allergy to efgartigimod alfa, hyaluronidase, or any of the other ingredients in VYVGART HYTRULO. VYVGART HYTRULO can cause serious allergic reactions and a decrease in blood pressure leading to fainting.

VYVGART HYTRULO may cause serious side effects, including:

- **Infection.** VYVGART HYTRULO may increase the risk of infection. The most common infections for efgartigimod alfa-fcab-treated patients were urinary tract and respiratory tract infections. Signs or symptoms of an infection may

include fever, chills, frequent and/or painful urination, cough, pain and blockage of nasal passages/sinus, wheezing, shortness of breath, fatigue, sore throat, excess phlegm, nasal discharge, back pain, and/or chest pain.

- **Allergic Reactions (hypersensitivity reactions).**

VYVGART HYTRULO can cause allergic reactions such as rashes, swelling under the skin, and shortness of breath. Hives were also observed in patients treated with VYVGART HYTRULO. Serious allergic reactions, such as trouble breathing and decrease in blood pressure leading to fainting have been reported with efgartigimod alfa-fcab.

- **Infusion-Related Reactions.**

VYVGART HYTRULO can cause infusion-related reactions. The most frequent symptoms and signs reported with efgartigimod alfa-fcab were high blood pressure, chills, shivering, and chest, abdominal, and back pain.

Tell your doctor if you have signs or symptoms of an infection, allergic reaction, or infusion-related reaction. These can happen while you are receiving your VYVGART HYTRULO treatment or afterward. Your doctor may need to pause or stop your treatment. Contact your doctor immediately if you have signs or symptoms of a serious allergic reaction.

Before taking VYVGART HYTRULO, tell your doctor if you:

- take any medicines, including prescription and non-prescription medicines, supplements, or herbal medicines,
- have received or are scheduled to receive a vaccine (immunization), or
- have any allergies or medical conditions, including if you are pregnant or planning to become pregnant, or are breastfeeding.

What are the common side effects of VYVGART HYTRULO?

The most common side effects in efgartigimod-alfa-fcab-treated patients were respiratory tract infection, headache, and urinary tract infection. Additional common side

effects with VYVGART HYTRULO are injection site reactions, including rash, redness of the skin, itching sensation, bruising, pain, and hives.

These are not all the possible side effects of VYVGART HYTRULO.

Call your doctor for medical advice about side effects. You may report side effects to the US Food and Drug Administration at 1-800-FDA-1088.

Please see the full Prescribing Information for VYVGART HYTRULO and talk to your doctor.

Pregnancy Registry:

There is a pregnancy registry for pregnant women who take VYVGART Hytrulo. The purpose of this registry is to collect information about the health of you and your baby if you take VYVGART Hytrulo during pregnancy.

To learn more, call 1-855-272-6524 or visit www.VYVGARTpregnancy.com. You may also talk to your healthcare provider about how you can take part in this registry.

A first-of-its-kind CIDP treatment—VYVGART Hytrulo

VYVGART[®] Hytrulo
(efgartigimod alfa and hyaluronidase-qvfc)
Subcutaneous Injection
180 mg/mL and 2000 U/mL vial



A NEW approach to CIDP

VYVGART Hytrulo is the first new class of CIDP treatment in over 30 years.



Proven to lower the risk of CIDP getting worse

Patients taking VYVGART Hytrulo maintained their arm and leg function for longer than those taking placebo.



A first for CIDP

One subcutaneous injection given weekly that takes ~30 to 90 seconds.*



A dedicated Nurse Case Manager

Provides personalized support that can help you navigate insurance, offer resources, and answer questions.

*After administering your injection, your healthcare provider will monitor you for allergic reactions for at least 30 minutes.

CIDP=chronic inflammatory demyelinating polyneuropathy

Visit [VYVGARTHytruloCIDP.com/glossary](https://vvygarthytruloCIDP.com/glossary) for a glossary of terms.

Ask your doctor if
VYVGART Hytrulo
is right for you



Visit
liveVYVIDLY.com
for helpful resources
and information

live
VYVIDLY

What is VYVGART[®] HYTRULO (efgartigimod alfa and hyaluronidase-qvfc)?

VYVGART HYTRULO is a prescription medicine used for the treatment of adult patients with chronic inflammatory demyelinating polyneuropathy (CIDP)

SELECT IMPORTANT SAFETY INFORMATION

Do not use VYVGART HYTRULO if you have a serious allergy to efgartigimod alfa, hyaluronidase, or any of the other ingredients in VYVGART HYTRULO. VYVGART HYTRULO can cause serious allergic reactions and a decrease in blood pressure leading to fainting.

Please see Important Safety Information throughout. Please see the full Prescribing Information for VYVGART HYTRULO.

VYVGART is a registered trademark of argenx. VYVGART Hytrulo is a trademark of argenx.
For U.S. audiences only. ©2024 argenx US-VYV_HYT-24-00020 V1 07/2024

argenx